Roseola Infantum Treatment & Management
- Author: Christopher R Gorman, MD; Chief Editor: William D James, MD more...
At present, no medical antiviral therapy is available for human herpesvirus 6 (HHV-6) infection that causes roseola. Thus, treatment of roseola infantum is supportive. However, in 2002, Rapaport et al reported that antiviral prophylaxis with ganciclovir may prevent HHV-6 reactivation in high-risk bone marrow transplant patients. Further double-blinded randomized studies are needed.
Short- or long-term antiseizure medications are not recommended for infants who have had a febrile seizure secondary to roseola.
Inpatient care for roseola infantum consists of support with antipyretics and treatment of gastroenterologic, respiratory, hematologic, or CNS complications.
A pediatric consultation is recommended for infants with roseola infantum who have febrile seizures.
In roseola infantum, complications are rare. Given that seroconversion is practically universal, finding any of the complications that have been reported in the gastrointestinal, central nervous, pulmonary, and hematopoietic systems is rare.
Children who have seizures with roseola are not expected to have further febrile or nonfebrile seizures.
Because seroconversion in the United States is nearly 100%, isolation is not indicated. The infection is spread through saliva in both the acute phase and the chronic phase.
No risk appears to be present to pregnant women exposed to roseola. Care must be taken to distinguish this from rubella. No reports of infection or complications following exposure exist. This is probably because of the nearly universal seroconversion and latent infection. No sequelae of intrauterine infection are known. Isolation is not indicated.
Vinnard C, Barton T, Jerud E, Blumberg E. A report of human herpesvirus 6-associated encephalitis in a solid organ transplant recipient and a review of previously published cases. Liver Transpl. 2009 Oct. 15(10):1242-6. [Medline].
Kittaka S, Hasegawa S, Ito Y, Ohbuchi N, Suzuki E, Kawano S, et al. Serum levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in human herpesvirus-6-infected infants with or without febrile seizures. J Infect Chemother. 2014 Nov. 20 (11):716-21. [Medline].
Zerr DM, Meier AS, Selke SS, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med. 2005 Feb 24. 352(8):768-76. [Medline].
Vianna RA, de Oliveira SA, Camacho LA, et al. Role of human herpesvirus 6 infection in young Brazilian children with rash illnesses. Pediatr Infect Dis J. 2008 Jun. 27(6):533-7. [Medline].
Magalhães Ide M, Martins RV, Vianna RO, Moysés N, Afonso LA, Oliveira SA, et al. Detection of human herpesvirus 7 infection in young children presenting with exanthema subitum. Mem Inst Oswaldo Cruz. 2011 May. 106(3):371-3. [Medline].
Ward KN. The natural history and laboratory diagnosis of human herpesviruses-6 and -7 infections in the immunocompetent. J Clin Virol. 2005 Mar. 32(3):183-93. [Medline].
Ward KN, Andrews NJ, Verity CM, Miller E, Ross EM. Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland. Arch Dis Child. 2005 Jun. 90(6):619-23. [Medline].
Stone RC, Micali GA, Schwartz RA. Roseola infantum and its causal human herpesviruses. Int J Dermatol. 2014 Apr. 53(4):397-403. [Medline].
Rapaport D, Engelhard D, Tagger G, Or R, Frenkel N. Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients. Transpl Infect Dis. 2002 Mar. 4(1):10-6. [Medline].